Corvus Pharmaceuticals, Inc. (CRVS) stock
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.64+0.02 (+0.19%)
Close on Nov 13, 2026Market cap $895.05MP/E –Yield –
Corvus Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Corvus Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was -$67.57M. For fiscal 2025 it was -$42.87M. The highest annual figure on record is -$13.62M in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$42.87M | – |
| FY2024 | Dec 31, 2024 | -$27.46M | – |
| FY2023 | Dec 31, 2023 | -$23.26M | – |
| FY2022 | Dec 31, 2022 | -$32.20M | – |
| FY2021 | Dec 31, 2021 | -$38.17M | – |
| FY2020 | Dec 31, 2020 | -$43.13M | – |
| FY2019 | Dec 31, 2019 | -$48.11M | – |
| FY2018 | Dec 31, 2018 | -$48.38M | – |
| FY2017 | Dec 31, 2017 | -$55.68M | – |
| FY2016 | Dec 31, 2016 | -$36.38M | – |
| FY2015 | Dec 31, 2015 | -$13.62M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$21.27M | – |
| Q2 FY2026 | Jun 30, 2026 | -$19.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.85M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.19M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.09M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.24M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.59M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.38M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.33M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.35M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.74M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.61M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.09M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.26M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.33M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.41M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.99M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.92M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.04M | – |
| Q1 FY2018 | Mar 31, 2018 | -$14.43M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.97M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.73M | – |
| Q2 FY2017 | Jun 30, 2017 | -$14.97M | – |
| Q1 FY2017 | Mar 31, 2017 | -$16.01M | – |
See a number that looks wrong?